Glaukos Corporation Announces Third Quarter 2020 Financial Results

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2020. Key highlights include: Net sales of $64.8 million in Q3 2020, compared to $58.5 million in Q3 2019. Glaucoma net sales of $51.9 million and Corneal Health net sales of $12.9 million in

Click to view original post